Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 135 entries
Sorted by: Best Match Show Resources per page
Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy.

F1000Research

Wardhan R, Chelly J.
PMID: 29225793
F1000Res. 2017 Nov 29;6:2065. doi: 10.12688/f1000research.12286.1. eCollection 2017.

In this review, we discuss advances in acute pain management, including the recent report of the joint American Pain Society and American Academy of Pain Medicine task force on the classification of acute pain, the role of psychosocial factors,...

Cite
Wardhan R, Chelly J. Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy. F1000Res. 2017;6:2065doi: 10.12688/f1000research.12286.1.
Wardhan, R., & Chelly, J. (2017). Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy. F1000Research, 62065. https://doi.org/10.12688/f1000research.12286.1
Wardhan, Richa, and Chelly, Jacques. "Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy." F1000Research vol. 6 (2017): 2065. doi: https://doi.org/10.12688/f1000research.12286.1
Wardhan R, Chelly J. Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy. F1000Res. 2017 Nov 29;6:2065. doi: 10.12688/f1000research.12286.1. eCollection 2017. PMID: 29225793; PMCID: PMC5710326.
Copy Download .nbib Format: NLM
Barred from better medicine? Reexamining regulatory barriers to the inclusion of prisoners in research.

Journal of law and the biosciences

Huang E, Cauley J, Wagner JK.
PMID: 28852561
J Law Biosci. 2017 Jan 10;4(1):159-174. doi: 10.1093/jlb/lsw064. eCollection 2017 Apr.

In 2015, President Obama announced plans for the Precision Medicine Initiative

Cite
Huang E, Cauley J, Wagner JK. Barred from better medicine? Reexamining regulatory barriers to the inclusion of prisoners in research. J Law Biosci. 2017;4(1):159-174doi: 10.1093/jlb/lsw064.
Huang, E., Cauley, J., & Wagner, J. K. (2017). Barred from better medicine? Reexamining regulatory barriers to the inclusion of prisoners in research. Journal of law and the biosciences, 4(1), 159-174. https://doi.org/10.1093/jlb/lsw064
Huang, Elaine, et al. "Barred from better medicine? Reexamining regulatory barriers to the inclusion of prisoners in research." Journal of law and the biosciences vol. 4,1 (2017): 159-174. doi: https://doi.org/10.1093/jlb/lsw064
Huang E, Cauley J, Wagner JK. Barred from better medicine? Reexamining regulatory barriers to the inclusion of prisoners in research. J Law Biosci. 2017 Jan 10;4(1):159-174. doi: 10.1093/jlb/lsw064. eCollection 2017 Apr. PMID: 28852561; PMCID: PMC5570691.
Copy Download .nbib Format: NLM
Does metformin exposure before ICU stay have any impact on patients' outcome? A retrospective cohort study of diabetic patients.

Annals of intensive care

Jochmans S, Alphonsine JE, Chelly J, Vong LVP, Sy O, Rolin N, Ellrodt O, Monchi M, Vinsonneau C.
PMID: 29198069
Ann Intensive Care. 2017 Dec 02;7(1):116. doi: 10.1186/s13613-017-0336-8.

BACKGROUND: Impact of metformin exposure before ICU stay remains controversial. Metformin is thought to induce lactic acidosis and haemodynamic instability but may reduce ICU mortality. We evaluated its influence on outcome in diabetic patients admitted in the ICU and...

Cite
Jochmans S, Alphonsine JE, Chelly J, et al. Does metformin exposure before ICU stay have any impact on patients' outcome? A retrospective cohort study of diabetic patients. Ann Intensive Care. 2017;7(1):116doi: 10.1186/s13613-017-0336-8.
Jochmans, S., Alphonsine, J. E., Chelly, J., Vong, L. V. P., Sy, O., Rolin, N., Ellrodt, O., Monchi, M., & Vinsonneau, C. (2017). Does metformin exposure before ICU stay have any impact on patients' outcome? A retrospective cohort study of diabetic patients. Annals of intensive care, 7(1), 116. https://doi.org/10.1186/s13613-017-0336-8
Jochmans, Sebastien, et al. "Does metformin exposure before ICU stay have any impact on patients' outcome? A retrospective cohort study of diabetic patients." Annals of intensive care vol. 7,1 (2017): 116. doi: https://doi.org/10.1186/s13613-017-0336-8
Jochmans S, Alphonsine JE, Chelly J, Vong LVP, Sy O, Rolin N, Ellrodt O, Monchi M, Vinsonneau C. Does metformin exposure before ICU stay have any impact on patients' outcome? A retrospective cohort study of diabetic patients. Ann Intensive Care. 2017 Dec 02;7(1):116. doi: 10.1186/s13613-017-0336-8. PMID: 29198069; PMCID: PMC5712297.
Copy Download .nbib Format: NLM
Characterizing Bias Due to Differential Exposure Ascertainment in Electronic Health Record Data.

Health services & outcomes research methodology

Hubbard RA, Lett E, Ho GYF, Chubak J.
PMID: 34366704
Health Serv Outcomes Res Methodol. 2021 Sep;21(3):309-323. doi: 10.1007/s10742-020-00235-3. Epub 2021 Jan 04.

Data derived from electronic health records (EHR) are heterogeneous with availability of specific measures dependent on the type and timing of patients' healthcare interactions. This creates a challenge for research using EHR-derived exposures because gold-standard exposure data, determined by...

Cite
Hubbard RA, Lett E, Ho GYF, et al. Characterizing Bias Due to Differential Exposure Ascertainment in Electronic Health Record Data. Health Serv Outcomes Res Methodol. 2021;21(3):309-323doi: 10.1007/s10742-020-00235-3.
Hubbard, R. A., Lett, E., Ho, G. Y. F., & Chubak, J. (2021). Characterizing Bias Due to Differential Exposure Ascertainment in Electronic Health Record Data. Health services & outcomes research methodology, 21(3), 309-323. https://doi.org/10.1007/s10742-020-00235-3
Hubbard, Rebecca A, et al. "Characterizing Bias Due to Differential Exposure Ascertainment in Electronic Health Record Data." Health services & outcomes research methodology vol. 21,3 (2021): 309-323. doi: https://doi.org/10.1007/s10742-020-00235-3
Hubbard RA, Lett E, Ho GYF, Chubak J. Characterizing Bias Due to Differential Exposure Ascertainment in Electronic Health Record Data. Health Serv Outcomes Res Methodol. 2021 Sep;21(3):309-323. doi: 10.1007/s10742-020-00235-3. Epub 2021 Jan 04. PMID: 34366704; PMCID: PMC8336686.
Copy Download .nbib Format: NLM
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia.

Leukemia

Fattizzo B, Ireland R, Dunlop A, Yallop D, Kassam S, Large J, Gandhi S, Muus P, Manogaran C, Sanchez K, Consonni D, Barcellini W, Mufti GJ, Marsh JCW, Kulasekararaj AG.
PMID: 33664463
Leukemia. 2021 Nov;35(11):3223-3231. doi: 10.1038/s41375-021-01190-9. Epub 2021 Mar 04.

In this large single-centre study, we report high prevalence (25%) of, small (

Cite
Fattizzo B, Ireland R, Dunlop A, et al. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia. 2021;35(11):3223-3231doi: 10.1038/s41375-021-01190-9.
Fattizzo, B., Ireland, R., Dunlop, A., Yallop, D., Kassam, S., Large, J., Gandhi, S., Muus, P., Manogaran, C., Sanchez, K., Consonni, D., Barcellini, W., Mufti, G. J., Marsh, J. C. W., & Kulasekararaj, A. G. (2021). Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia, 35(11), 3223-3231. https://doi.org/10.1038/s41375-021-01190-9
Fattizzo, Bruno, et al. "Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia." Leukemia vol. 35,11 (2021): 3223-3231. doi: https://doi.org/10.1038/s41375-021-01190-9
Fattizzo B, Ireland R, Dunlop A, Yallop D, Kassam S, Large J, Gandhi S, Muus P, Manogaran C, Sanchez K, Consonni D, Barcellini W, Mufti GJ, Marsh JCW, Kulasekararaj AG. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia. 2021 Nov;35(11):3223-3231. doi: 10.1038/s41375-021-01190-9. Epub 2021 Mar 04. PMID: 33664463; PMCID: PMC8550969.
Copy Download .nbib Format: NLM
The Design of a Reflection Electron Energy Loss Spectrometer Attachment for Low Voltage Scanning Electron Microscopy.

Materials (Basel, Switzerland)

Chuah J, Khursheed A.
PMID: 34947108
Materials (Basel). 2021 Dec 07;14(24). doi: 10.3390/ma14247511.

This paper presents the design of a reflection electron energy spectrometer (REELS) attachment for low voltage scanning electron microscopy (LVSEM) applications. The design is made by carrying out a scattered electron trajectory ray paths simulation. The spectrometer attachment is...

Cite
Chuah J, Khursheed A. The Design of a Reflection Electron Energy Loss Spectrometer Attachment for Low Voltage Scanning Electron Microscopy. Materials (Basel). 2021;14(24)doi: 10.3390/ma14247511.
Chuah, J., & Khursheed, A. (2021). The Design of a Reflection Electron Energy Loss Spectrometer Attachment for Low Voltage Scanning Electron Microscopy. Materials (Basel, Switzerland), 14(24), . https://doi.org/10.3390/ma14247511
Chuah, Jonathan, and Khursheed, Anjam. "The Design of a Reflection Electron Energy Loss Spectrometer Attachment for Low Voltage Scanning Electron Microscopy." Materials (Basel, Switzerland) vol. 14,24 (2021). doi: https://doi.org/10.3390/ma14247511
Chuah J, Khursheed A. The Design of a Reflection Electron Energy Loss Spectrometer Attachment for Low Voltage Scanning Electron Microscopy. Materials (Basel). 2021 Dec 07;14(24). doi: 10.3390/ma14247511. PMID: 34947108; PMCID: PMC8706004.
Copy Download .nbib Format: NLM
Symptom Burden in Long-Term Survivors of Head and Neck Cancer: Patient-Reported Versus Clinical Data.

EGEMS (Washington, DC)

Pocobelli G, Ziebell R, Fujii M, Hutcheson KA, Chang S, McClure JB, Chubak J.
PMID: 31328132
EGEMS (Wash DC). 2019 Jul 10;7(1):25. doi: 10.5334/egems.271.

INTRODUCTION: The symptom burden faced by long-term head and neck cancer survivors is not well understood. In addition, the accuracy of clinical data sources for symptom ascertainment is not clear.OBJECTIVE: To 1) describe the prevalence of symptoms in 5-year...

Cite
Pocobelli G, Ziebell R, Fujii M, et al. Symptom Burden in Long-Term Survivors of Head and Neck Cancer: Patient-Reported Versus Clinical Data. EGEMS (Wash DC). 2019;7(1):25doi: 10.5334/egems.271.
Pocobelli, G., Ziebell, R., Fujii, M., Hutcheson, K. A., Chang, S., McClure, J. B., & Chubak, J. (2019). Symptom Burden in Long-Term Survivors of Head and Neck Cancer: Patient-Reported Versus Clinical Data. EGEMS (Washington, DC), 7(1), 25. https://doi.org/10.5334/egems.271
Pocobelli, Gaia, et al. "Symptom Burden in Long-Term Survivors of Head and Neck Cancer: Patient-Reported Versus Clinical Data." EGEMS (Washington, DC) vol. 7,1 (2019): 25. doi: https://doi.org/10.5334/egems.271
Pocobelli G, Ziebell R, Fujii M, Hutcheson KA, Chang S, McClure JB, Chubak J. Symptom Burden in Long-Term Survivors of Head and Neck Cancer: Patient-Reported Versus Clinical Data. EGEMS (Wash DC). 2019 Jul 10;7(1):25. doi: 10.5334/egems.271. PMID: 31328132; PMCID: PMC6625536.
Copy Download .nbib Format: NLM
Duration of prone position sessions: a prospective cohort study.

Annals of intensive care

Jochmans S, Mazerand S, Chelly J, Pourcine F, Sy O, Thieulot-Rolin N, Ellrodt O, Mercier Des Rochettes E, Michaud G, Serbource-Goguel J, Vinsonneau C, Vong LVP, Monchi M.
PMID: 32449068
Ann Intensive Care. 2020 May 24;10(1):66. doi: 10.1186/s13613-020-00683-7.

BACKGROUND: Prone position (PP) is highly recommended in moderate-to-severe ARDS. However, the optimal duration of PP sessions remains unclear. We searched to evaluate the time required to obtain the maximum physiological effect, and to search for parameters related to...

Cite
Jochmans S, Mazerand S, Chelly J, et al. Duration of prone position sessions: a prospective cohort study. Ann Intensive Care. 2020;10(1):66doi: 10.1186/s13613-020-00683-7.
Jochmans, S., Mazerand, S., Chelly, J., Pourcine, F., Sy, O., Thieulot-Rolin, N., Ellrodt, O., Mercier Des Rochettes, E., Michaud, G., Serbource-Goguel, J., Vinsonneau, C., Vong, L. V. P., & Monchi, M. (2020). Duration of prone position sessions: a prospective cohort study. Annals of intensive care, 10(1), 66. https://doi.org/10.1186/s13613-020-00683-7
Jochmans, Sebastien, et al. "Duration of prone position sessions: a prospective cohort study." Annals of intensive care vol. 10,1 (2020): 66. doi: https://doi.org/10.1186/s13613-020-00683-7
Jochmans S, Mazerand S, Chelly J, Pourcine F, Sy O, Thieulot-Rolin N, Ellrodt O, Mercier Des Rochettes E, Michaud G, Serbource-Goguel J, Vinsonneau C, Vong LVP, Monchi M. Duration of prone position sessions: a prospective cohort study. Ann Intensive Care. 2020 May 24;10(1):66. doi: 10.1186/s13613-020-00683-7. PMID: 32449068; PMCID: PMC7245995.
Copy Download .nbib Format: NLM
Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics.

Preventive medicine

Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC.
PMID: 34762966
Prev Med. 2021 Nov 08;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 08.

Since 2012, cervical cancer screening guidelines allow for choice of screening test for women age 30-65 years (i.e., Pap every 3 years or Pap with human papillomavirus co-testing every 5 years). Intended to give patients and providers options, this...

Cite
Haas JS, Cheng D, Yu L, et al. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2021;154:106871doi: 10.1016/j.ypmed.2021.106871.
Haas, J. S., Cheng, D., Yu, L., Atlas, S. J., Clark, C., Feldman, S., Silver, M. I., Kamineni, A., Chubak, J., Pocobelli, G., Tiro, J. A., & Kobrin, S. C. (2021). Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Preventive medicine, 154106871. https://doi.org/10.1016/j.ypmed.2021.106871
Haas, Jennifer S, et al. "Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics." Preventive medicine vol. 154 (2021): 106871. doi: https://doi.org/10.1016/j.ypmed.2021.106871
Haas JS, Cheng D, Yu L, Atlas SJ, Clark C, Feldman S, Silver MI, Kamineni A, Chubak J, Pocobelli G, Tiro JA, Kobrin SC. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2021 Nov 08;154:106871. doi: 10.1016/j.ypmed.2021.106871. Epub 2021 Nov 08. PMID: 34762966.
Copy Download .nbib Format: NLM
Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study.

JMIR cancer

A'mar T, Beatty JD, Fedorenko C, Markowitz D, Corey T, Lange J, Schwartz SM, Huang B, Chubak J, Etzioni R.
PMID: 32970603
JMIR Cancer. 2020 Sep 24;6(2):e23821. doi: 10.2196/23821.

[This corrects the article DOI: 10.2196/18143.].

Cite
A'mar T, Beatty JD, Fedorenko C, et al. Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. JMIR Cancer. 2020;6(2):e23821doi: 10.2196/23821.
A'mar, T., Beatty, J. D., Fedorenko, C., Markowitz, D., Corey, T., Lange, J., Schwartz, S. M., Huang, B., Chubak, J., & Etzioni, R. (2020). Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. JMIR cancer, 6(2), e23821. https://doi.org/10.2196/23821
A'mar, Teresa, et al. "Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study." JMIR cancer vol. 6,2 (2020): e23821. doi: https://doi.org/10.2196/23821
A'mar T, Beatty JD, Fedorenko C, Markowitz D, Corey T, Lange J, Schwartz SM, Huang B, Chubak J, Etzioni R. Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. JMIR Cancer. 2020 Sep 24;6(2):e23821. doi: 10.2196/23821. PMID: 32970603; PMCID: PMC7545323.
Copy Download .nbib Format: NLM
Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer.

Case reports in nephrology

Nlandu Y, Pourcine F, Vong LVP, Chelly J, Jochmans S, Mazerand S, Monchi M.
PMID: 31827954
Case Rep Nephrol. 2019 Nov 19;2019:8591283. doi: 10.1155/2019/8591283. eCollection 2019.

Cancer-associated thrombotic microangiopathy (TMA) refers to a group of disorders characterized by microangiopathic haemolytic anemia, thrombocytopenia, and ischemic organ damage. TMA manifestations can be induced by cancer or by chemotherapy. We report the case of a 64-year-old man with...

Cite
Nlandu Y, Pourcine F, Vong LVP, et al. Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer. Case Rep Nephrol. 2019;2019:8591283doi: 10.1155/2019/8591283.
Nlandu, Y., Pourcine, F., Vong, L. V. P., Chelly, J., Jochmans, S., Mazerand, S., & Monchi, M. (2019). Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer. Case reports in nephrology, 20198591283. https://doi.org/10.1155/2019/8591283
Nlandu, Yannick, et al. "Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer." Case reports in nephrology vol. 2019 (2019): 8591283. doi: https://doi.org/10.1155/2019/8591283
Nlandu Y, Pourcine F, Vong LVP, Chelly J, Jochmans S, Mazerand S, Monchi M. Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer. Case Rep Nephrol. 2019 Nov 19;2019:8591283. doi: 10.1155/2019/8591283. eCollection 2019. PMID: 31827954; PMCID: PMC6885798.
Copy Download .nbib Format: NLM
Utility of Early Posttreatment PET/CT Evaluation Using FDG or .

AJR. American journal of roentgenology

Reizine E, Chalaye J, Mule S, Regnault H, Perrin C, Calderaro J, Laurent A, Amaddeo G, Kobeiter H, Tacher V, Itti E, Luciani A.
PMID: 34494448
AJR Am J Roentgenol. 2021 Dec 29;1-11. doi: 10.2214/AJR.21.26485. Epub 2021 Dec 29.

No abstract available.

Cite
Reizine E, Chalaye J, Mule S, et al. Utility of Early Posttreatment PET/CT Evaluation Using FDG or . AJR Am J Roentgenol. 2021;1-11doi: 10.2214/AJR.21.26485.
Reizine, E., Chalaye, J., Mule, S., Regnault, H., Perrin, C., Calderaro, J., Laurent, A., Amaddeo, G., Kobeiter, H., Tacher, V., Itti, E., & Luciani, A. (2021). Utility of Early Posttreatment PET/CT Evaluation Using FDG or . AJR. American journal of roentgenology, 1-11. https://doi.org/10.2214/AJR.21.26485
Reizine, Edouard, et al. "Utility of Early Posttreatment PET/CT Evaluation Using FDG or ." AJR. American journal of roentgenology vol. (2021): 1-11. doi: https://doi.org/10.2214/AJR.21.26485
Reizine E, Chalaye J, Mule S, Regnault H, Perrin C, Calderaro J, Laurent A, Amaddeo G, Kobeiter H, Tacher V, Itti E, Luciani A. Utility of Early Posttreatment PET/CT Evaluation Using FDG or . AJR Am J Roentgenol. 2021 Dec 29;1-11. doi: 10.2214/AJR.21.26485. Epub 2021 Dec 29. PMID: 34494448.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 135 entries